Arkolith/Insider Trading/AKTS/Form 4

Herrmann Ken

DirectorAktis Oncology, Inc. (AKTS) · full profile →Form 4 · filed Jul 22, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$119K
Net Open-Market Flow
-$119K
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 20, 2026Option exercise(M)4K$0.08$2804K
Jul 20, 2026Option exercise(M)1K$1.91$3K5K
Jul 20, 2026Sell(S)4K$24.56$86K1K
Jul 20, 2026Sell(S)1K$24.56$33K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 20, 2026Option exercise(M)4K—$00
Jul 20, 2026Option exercise(M)1K—$018K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-310991) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Aktis Oncology, Inc.

Build

Ask your agent about AKTS insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001193125-26-310991"
Ask your agent
Use Arkolith to summarize insider buying and selling at Aktis Oncology, Inc.
over the last 90 days and cite the filings.